As the incoming class of independent biotechs look to build on their clinical and commercial successes, a handful are expanding beyond the technology that got them there, bringing in new modalities to complement their platforms and bolster their core focus areas.
It’s become clear that more biotechs are taking the commercial reins for their own products. An April analysis by BioCentury found a steady rise in the number of biotechs launching their first commercial products in the U.S. over the last five years (see “Rise of the Independents: Biotechs Go to Market”).
In some cases, these companies got to this inflection point via a series of collaborations that saw them give up much of the commercial rights to their products, and now, with their first solo launches, they’re shifting strategy to retain more commercial control (see “Independents’ Day: After Their First Solo Launch, Biotechs Look to New Partnering Strategies”).
But at least two biotechs are taking a different path forward, turning to additional modalities rather than changing their BD strategy to build on their successful technologies.
Regeneron Pharmaceuticals Inc. and Seattle Genetics Inc., both more than five years on from their first